BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. PRIM
6. META
7. SPY
8. DPZ
9. NAVN
10. NVDA

Go back to BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization

BioXcel Therapeutics (BTAI) Misses Q2 EPS by 16c

August 14, 2023 7:04 AM EDT

BioXcel Therapeutics (NASDAQ: BTAI) reported Q2 EPS of ($1.83), $0.16 worse than the analyst estimate of ($1.67). Revenue for the quarter came in at $457 thousand versus the consensus estimate of $420.56 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

... More